This provider's $10.2M in total Medicare payments ranks in the 91th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 4248% from 2022 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 4248% in 2023
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2022 | $357.13 | $349.98 | 1.02x | $7.15 | $229.6K | 656 | 9 |
| 2023 | $197.51 | $180.88 | 1.09x | $16.63 | $10.0M | 55.2K | 29 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 81419 | Gene analysis panel for evaluation of genes associated with epilepsy | 1.1K | $2.6M | $2.4K | 1.02x |
| 81325 | Gene analysis (peripheral myelin protein 22), full sequence analysis | 1.1K | $803.8K | $754.00 | 1.02x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 13.3K | $456.0K | $34.39 | 2.04x |
| 81317 | Gene analysis (postmeiotic segregation increased 2 [s cerevisiae]) full sequence analysis | 567 | $375.9K | $662.97 | 1.02x |
| 81307 | Gene analysis (partner and localizer of brca2) full sequence analysis | 564 | $370.2K | $656.40 | 1.02x |
| 81298 | Gene analysis (muts homolog 6 [e coli]) full sequence analysis | 579 | $364.2K | $629.01 | 1.02x |
| 81249 | Gene analysis (glucose-6-phosphate dehydrogenase) full sequence analysis | 601 | $353.4K | $588.00 | 1.02x |
| 81238 | Gene analysis (coagulation factor ix) full sequence analysis | 567 | $333.4K | $588.00 | 1.02x |
| 81336 | Gene analysis (survival of motor neuron 1, telomeric) of full sequence | 1.1K | $316.9K | $295.32 | 1.02x |
| 81223 | Gene analysis (cystic fibrosis transmembrane conductance regular) full gene sequence | 603 | $294.9K | $489.02 | 1.02x |
| 81309 | Gene analysis (partner and localizer of brca2) targeted sequence analysis | 1.1K | $285.0K | $269.33 | 1.02x |
| 81189 | Gene analysis (cystatin b) of full sequence | 1.1K | $279.4K | $260.87 | 1.02x |
| 81286 | Gene analysis (frataxin) of full sequence | 1.0K | $275.5K | $269.33 | 1.02x |
| 81191 | Gene analysis (neurotrophic receptor tyrosine kinase 1) translocation analysis | 1.1K | $219.6K | $203.16 | 1.02x |
| 81192 | Gene analysis (neurotrophic receptor tyrosine kinase 2) translocation analysis | 1.1K | $219.6K | $203.16 | 1.02x |
| 81177 | Gene analysis (atropin 1) for abnormal alleles | 1.1K | $144.2K | $134.26 | 1.02x |
| 81271 | Gene analysis (huntingtin) for abnormal alleles | 1.1K | $144.1K | $134.26 | 1.02x |
| 81178 | Gene analysis (ataxin 1) for abnormal alleles | 1.1K | $143.9K | $134.26 | 1.02x |
| 81180 | Gene analysis (ataxin 3) for abnormal alleles | 1.1K | $143.9K | $134.26 | 1.02x |
| 81182 | Gene analysis (ataxin 8 opposite strand [non-protein coding]) for abnormal alleles | 1.1K | $143.9K | $134.26 | 1.02x |
This provider submits charges 1.09 times higher than what Medicare actually pays.
A markup ratio of 1.09x means for every $100 Medicare pays, this provider initially charges $109. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in TX for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Clinical Pathology Laboratories, Inc. | Austin, TX | $541.0M | ⚠️ Flagged |
| Quest Diagnostics Clinical Laboratories Inc | Irving, TX | $453.2M | ⚠️ Flagged |
| Laboratory Corporation Of America | Dallas, TX | $389.6M | ⚠️ Flagged |
| Quest Diagnostics Clinical Laboratories Inc | Houston, TX | $311.2M | ⚠️ Flagged |
| Laboratory Corporation Of America | Houston, TX | $299.4M | ⚠️ Flagged |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data